LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A. Kriegsman and Vice President of Business Development David Haen will provide a business update at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, at 11:30 a.m. Eastern time (8:30 a.m. Pacific Time). The conference will be held at the Waldorf=Astoria hotel in New York City.
“We are looking forward to an exciting and eventful year as we advance development of our promising oncology compounds in multiple clinical trials,” said Mr. Kriegsman. “Among the 2012 highlights, we expect to begin a Phase 2 clinical trial with INNO-206 in a yet undisclosed solid tumor indication in the first half of the year and expect to announce clinical data from our Phase 1b/2 clinical trial with INNO-206 primarily in patients with soft tissue sarcoma at the American Society of Clinical Oncology (ASCO) conference in June. We are delighted to present what we consider an intriguing investment opportunity at BIO CEO, the largest investor conference focused on established and emerging publicly traded biotech companies.”
A webcast of the presentation will be available on the Company’s new website at http://cytrx.com/investors/presentations.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. With its tumor-targeted doxorubicin conjugate INNO-206, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, is completing its ongoing Phase 1b/2 clinical trial and plans to initiate a Phase 2 trial for an undisclosed solid tumor indication in the first half of 2012. CytRx's pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and which is in a clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com.
Legend Securities, Inc.
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical